A photo of Cristina Tarango.

Cristina Tarango, MD


  • Medical Director, Hemophilia Treatment Center
  • Professor, UC Department of Pediatrics
I try to treat each patient the way I would want my family members to be cared for.
Cristina Tarango, MD

About

Biography

As a pediatric hematologist, I treat children with conditions such as hemophilia, von Willebrand disease, thrombosis (blood clots) and other blood conditions. I try to treat each patient the way I would want my family members to be cared for. It’s very important for patients and families to take an active role in their care and share in the decision-making.

I was influenced in my career choice by a wonderful pediatrician who cared for me when I was growing up. After I became a pediatrician, I chose the field of hematology because it’s so diverse and interesting. At Cincinnati Children’s, I enjoy working with our dedicated group of physicians as well as our excellent nurse care managers, social workers, child life specialists and other professionals who are so committed to supporting children with blood disorders.

In addition to patient care, I conduct research. My studies are focused on gaining a better understanding of thrombosis and its management in children. I am also involved with studies assessing different treatments for hemophilia, as well as evaluating the immune system in patients with hemophilia, both with and without inhibitors. Inhibitors are antibodies that can prevent treatments from working, which makes it more difficult to stop a bleeding episode.

Outside the hospital, I love spending time with my husband and daughter. I also enjoy traveling, reading and volunteering when I can.

MD: Stanford University School of Medicine, Stanford, CA, 2003.

Residency: Yale-New Haven Hospital, New Haven, CT, 2006.

Fellowship: University of Texas Southwestern Medical Center Dallas, Dallas, TX, 2009.

Certification: Pediatrics, 2006; Pediatric Hematology Oncology, 2011.

Interests

Pediatric bleeding disorders and thrombosis; quality improvement; medical education

Interests

Pediatric bleeding disorders and thrombosis; quality improvement; medical education

Additional Languages

Spanish

Insurance Information

Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.

View Insurance Information

Publications

Efficacy and safety of thrombolysis for pediatric venous thromboembolism: a systematic review and meta-analysis. Kawtharany, H; Azzam, M; Alkhader, A; Betensky, M; Hamarsha, Q; Abou Zeid, HK; Mansour, R; Tabak, C; Patel, P; Baghdadi, SL; Woods, G; Zia, A; Monagle, P; Mustafa, RA. Blood Advances. 2025; 9:5512-5527.

Post hoc analysis of bleeding episodes and clinically relevant pharmacokinetic parameters among children <12 years old with severe hemophilia A receiving once-weekly efanesoctocog alfa prophylaxis in the XTEND-Kids phase 3 multinational trial. Malec, L; Mathias, M; Dunn, AL; Nolan, B; Wong, N; Bystrická, L; Khan, U; Neill, G; Santagostino, E; Gunawardena, S; Tarango, C; Peyvandi, F. Journal of Thrombosis and Haemostasis. 2025; 23:3481-3491.

Inhibitors and Obesity: The Prevalence and Strength of Association in People With Haemophilia. Littner, L; Hu, J; Manuel, M; Gerber, C; Tarango, C. Haemophilia. 2025; 31:1226-1235.

Recurrent thrombosis and major bleeding in children treated for VTE. Lenahan, SF; Blackmore, A; Fenchel, M; Thomas, E; Palumbo, JS; Tarango, C. Blood Advances. 2025; 9:3824-3831.

Inhibitor development and clinical characteristics in children with severe hemophilia A in the ATHN 8 US cohort study. Thornburg, CD; van den Berg, HM; Chandler, M; Malec, L; Manuel, M; O'Neill, C; Recht, M; Taggart, E; Carpenter, SL; American Thrombosis and Hemostasis Network (ATHN) , . 2025; 2:100082.

American Society of Hematology/International Society on Thrombosis and Haemostasis 2024 updated guidelines for treatment of venous thromboembolism in pediatric patients. Monagle, P; Azzam, M; Bercovitz, R; Betensky, M; Bhat, R; Biss, T; Branchford, B; Brandão, LR; Chan, AK C; Faustino, VE S; Wilson, HP; Woods, G; Zia, A; Mustafa, RA. Blood Advances. 2025; 9:2587-2636.

Secondary Anticoagulation Use in Patients < 21 Years Old following Primary Anticoagulant Treatment for Provoked Venous Thromboembolism: Findings from the Kids-DOTT Trial. Wilson, HP; Mosha, M; Miller, A; Betensky, M; Amankwah, E; Fargo, J; Thornburg, CD; Tarango, C; Acharya, S; Male, C; Narang, S; Schulman, S; Goldenberg, NA. Seminars in Thrombosis and Hemostasis. 2025; 51:343-347.

Improving Time to Bleeding Disorder Treatment in the Emergency Department. Littner, L; Thomas, E; Mooney, L; Doyle, J; Hendrickson, J; Tarango, C. Pediatric Blood and Cancer. 2025; 72:e31570.

Perioperative Management with Efanesoctocog Alfa in Adults, Adolescents, and Children with Severe Hemophilia A in the Phase 3 XTEND Clinical Program. Chan, AK; Susen, S; Khoo, L; von Drygalski, A; Oldenburg, J; Shen, M; Peyvandi, F; Tarango, C; Chowdary, P; Mamikonian, L; Palmborg, H; Dumont, J; Santagostino, E; Hermans, C. Hamostaseologie. 2025; 45:s57-s58.

Duration of anticoagulation for venous thromboembolism in pediatric patients: Evaluation of the Duration of Therapy for Thrombosis in Children (Kids-DOTT) trial outcomes at 2 years. Goldenberg, NA; Schulman, S; Kittelson, JM; Abshire, TC; Casella, JF; Dale, R; Halperin, JL; Hanson, J; Kessler, CM; Manco-Johnson, MJ; McDevitt, L; Sidonio, RF; Spyropoulos, AC; Steg, PG; Bonaca, MP. Journal of Thrombosis and Haemostasis. 2025; 23:651-656.

Patient Ratings and Comments

All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent experience management company, Qualtrics. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey

Loading ...
Loading ...